Terra Reynolds

Terra’s experience includes representing:

Internal Investigations

• A pharmaceutical company in an internal investigation of alleged misconduct by a principal investigator during a clinical trial
• An international medical device company in an internal investigation of sales and marketing practices and corporate executive conduct
• An international pharmaceutical company in a review of its domestic compliance program
• A pharmaceutical company in a drug pricing dispute with a national pharmacy chain 
• A nationwide hospital system and healthcare management company in connection with internal investigations of individual and corporate compliance with policies and federal regulations
• A national medical device company in an internal investigation of sales and marketing practices following the publication of a short-seller report
• A physician-owned surgical hospital in connection with an internal investigation of compliance with federal regulations
• A manufacturer in an internal investigation of purported adulteration of a FDA-cleared product
• A medical device company in connection with an internal investigation into a cross-border supply chain issue
• A data analytics company in connection with an internal investigation regarding allegations of financial irregularities and employee misconduct
• A privately-owned sports entertainment company in an internal investigation of alleged employee misconduct
• A pharmaceutical company in connection with an internal review of its patient support program*
• An international tobacco company in connection with a review of whistleblower allegations regarding the compliance of its sales and marketing practices with FDA regulations
• An international generic manufacturer of opioids in connection with an internal review of its DEA compliance program
• A multinational pharmaceutical company in preparing a crisis management plan*

Government Investigations

• A medical waste management company in DOJ criminal and civil investigations of its DEA reverse distributor business
• A healthcare system CEO in a DOJ investigation of potential violations of the Foreign Corrupt Practices Act (FCPA) A health care provider in a DOJ criminal healthcare fraud investigation
• A former medical device company CEO in a DOJ criminal case involving allegations of healthcare fraud
• An ambulatory surgery center (ASC) in a DOJ criminal investigation involving allegations of medical necessity and healthcare fraud
• A nationwide healthcare management company and a physician-owned surgical hospital in the self-disclosures to the HHS-OIG and FCA investigations by the DOJ
• A genetic testing company in a DOJ criminal healthcare fraud investigation
• A medical device company in a DOJ criminal and civil investigation that resulted in a highly favorable hybrid civil resolution based on civil mistake-of-payment and FCA allegations 
• A nationwide hospital system in a DOJ FCA investigation, resulting in a declination to intervene and dismissal of the lawsuit
• A nationwide healthcare management company and a physician-owned surgical hospital in the favorable resolution of an FCA matter involving alleged AKS violations
• A former medical device company executive in a DOJ civil healthcare fraud investigation, resulting in the government declining to take enforcement action
• A medical device sales representative in a DOJ healthcare fraud investigation regarding alleged violations of the FCA and the AKS, resulting in a declination
• A former union executive in a DOJ criminal investigation into alleged embezzlement of union funds
• A private equity-backed provider of rehabilitation management services in the resolution of an FCA lawsuit without the imposition of a Corporate Integrity Agreement (CIA)
• A private equity-backed provider of rehabilitation management services in DOJ healthcare fraud investigations, resulting in declinations to intervene in whistleblower lawsuits
• A multinational pharmaceutical company in connection with a DOJ investigation into its patient support program, drug pricing, and specialty pharmacy issues*
• A domestic pharmaceutical company in connection with FDA and DOJ investigations into its sales and marketing practices*

Litigation

• A healthcare revenue cycle management company in a non-intervened qui tam lawsuit alleging violations of the FCA and AKS
• An international medical supply company in a series of patent infringement lawsuits against a competitor
• A leading provider of radiology imaging services in a civil racketeering and healthcare fraud lawsuit, resulting in a favorable resolution short of trial
• A manufacturer of automotive parts in patent litigation, resulting in a highly favorable jury verdict
• An international law firm in a defamation lawsuit, resulting in a dismissal of the complaint that was affirmed on appeal
• A wrongfully convicted individual in a civil rights lawsuit against the City of Chicago and individual officers
• A respondent in an International Chamber of Commerce (ICC) arbitration in Singapore concerning allegations of fraud arising from a multibillion-dollar acquisition of an international pharmaceutical company*

Transactional Diligence

• Buyers, sellers, sponsors, and underwriters in diligence for transactions, including initial public offerings, involving healthcare and life sciences companies

*Matter handled prior to joining Latham